New pangenotypic hepatitis C drug combinations recommended for approval in the European Union

Keith Alcorn
Published: 26 June 2017

Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European Union marketing approval in the next few months, manufacturers announced last week.

Drugs submitted for approval in the European Union must be approved by the CHMP before receiving marketing approval from the European Commission.

Pangenotypic treatments are suitable for all genotypes of hepatitis C. Pangenotypic products may simplify prescribing and treatment enrolment by removing the need for genotype testing and simplifying treatment. But, in settings where genotype testing is easily available, other considerations may be important for simplifying treatment, especially equal efficacy across different patient groups.

Maviret, a combination of the NS3/NS4 protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir, is recommended for approval as a treatment for hepatitis C genotypes 1-6. Maviret is manufactured by AbbVie.

Clinical trials of glecaprevir/pibrentasvir showed very high rates of sustained virologic response (97.5% across genotypes 1-6) and in harder-to-treat groups of people such as those with genotype 3, severe kidney disease or compensated cirrhosis.

The second product, Vosevi, is a combination of the NS5B polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir and the NS3/NS4 protease inhibitor voxilaprevir. Like Maviret, Vosevi is dosed once-daily. Vosevi is manufactured by Gilead Sciences.

Vosevi is also recommended for approval as a treatment for hepatitis C genotypes 1-6. Clinical trials to support the approval of Vosevi showed that the combination cured 95% of people with and without cirrhosis, and 96% of people with genotype 3 infection and cirrhosis, one of the hardest patient groups to cure.

Sofosbuvir and velpatasvir are already approved as a combination product, Epclusa, for the treatment of genotypes 1-6.

Final details of the duration of treatment with each product will be available when full marketing approval is granted by the European Commission later this year. Vosevi is expected to receive US marketing approval by August 2017 and Maviret is also undergoing US review.

Hepatitis information

For more information on hepatitis visit infohep.org.

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit infohep.org >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.